Ensereptide - ProMore Pharma
Alternative Names: PXL-01Latest Information Update: 25 Apr 2023
At a glance
- Originator PharmaSurgics
- Developer PharmaSurgics; ProMore Pharma; Technomark Life Sciences
- Class Glycoproteins; Peptides
- Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Plasminogen activator inhibitor-1 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Post-surgical adhesions
Highest Development Phases
- Phase III Post-surgical adhesions
Most Recent Events
- 20 Apr 2023 Adverse events and efficacy data from the phase II PHSU05 trial in Post-surgical adhesions (Prevention) released by ProMore Pharma
- 20 Apr 2023 ProMore Pharma completes the phase II PHSU05 trial in Post-surgical adhesions (Prevention)
- 20 Apr 2023 ProMore Pharma initiates the phase II PHSU05 trial in Post-surgical adhesions (Prevention) before April 2023